It is worth noting that although we focus on the key blood-based AD biomarkers for the AT(N) criteria (e.g., Aβ40, Aβ42, Aβ42/40 ratio, total-tau (t-tau), p-tau, NfL, brain-derived tau [BD-tau] and GFAP), we anticipate that these guidelines will generally be applicable to other types of blood biomarkers as well as discovery proteomic investigations. The gene discussed is MAPT; the disease is Alzheimer disease.